Joann Lindenfeld, MD
Cardiovascular Disease · Nashville, TNNPI 1386734069
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $210,626 of the $269,985 with a category attached, or 78.0%. 16 manufacturers reported payments, led by Abbott at 34.0% of the total. Reporting peaked in 2019 at $88,953 and has fallen 54.2% since, to $40,742 in 2025. Among cardiovascular disease clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $981.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$92K
- Cvrx, Inc.$36K
- Edwards Lifesciences$31K
- Boehringer Ingelheim International GmbH$23K
- Merck$21K
- Abiomed$16K
- plus $52K from 10 others
Across 25 payments — averaging $76,803 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.8M
- Sensible Medical Innovations Ltd$43K
- Cvrx, Inc.$28K
- Boston Scientific$28K
What the payments were for
- Consulting fees$210,62678%
- Speaking & faculty fees$30,81011%
- Travel & lodging$22,5948%
- Food & beverage$5,9552%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 124 | $91,762 |
| Cvrx, Inc. | 14 | $36,199 |
| Edwards Lifesciences | 40 | $31,009 |
| Boehringer Ingelheim International GmbH | 13 | $22,721 |
| Merck | 35 | $20,583 |
| Abiomed | 9 | $15,584 |
| Boehringer Ingelheim France S.a.s. | 3 | $12,949 |
| Boston Scientific | 14 | $10,526 |
| Kestra Medical Technology Services, Inc. | 2 | $10,400 |
| Eli Lilly | 3 | $6,950 |
| Vifor Pharma, Inc. | 2 | $4,266 |
| AstraZeneca | 4 | $3,474 |
| Biotronik Inc. | 2 | $3,200 |
| Astrazeneca UK Limited | 1 | $129 |
| Medtronic | 1 | $116 |
| Novartis | 8 | $116 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$36,147
- CardioMEMS HF System$32,530
- JARDIANCE$25,121
- Mitra Clip system$13,169
- CARDIOMEMS$12,413
- VERQUVO$12,077
- HeartMate$11,861
- Assure WCD$10,400
- MitraClip System$7,539
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$5,435
- MOUNJARO$4,550
- Veltassa$4,266
- GENERAL - THERAPIES$3,971
- MitraClip$3,967
- Acticor 7 VR-T DX$2,800
- Solia$2,800
- Plexa ProMRI$2,800
- Sentus$2,800
- Rivacor 7 DR-T$2,800
- Impella$2,713
How this compares
$269,985 in reported general payments places this provider in the 95th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 22 | $34,862 |
| JardianceEmpagliflozin | 26 | $26,429 |
| EliquisApixaban | 11 | $18,460 |
| Torsemide | 13 | $871 |
| Metoprolol Succinate | 40 | $834 |
| Losartan Potassium | 12 | $149 |
| Spironolactone | 28 | $146 |
| Furosemide | 12 | $101 |
| Atorvastatin Calcium | 12 | $70 |
| Carvedilol | 12 | $38 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $116 | $34,86222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Nashville
- Christopher EllisNashville$527K
- Andrew ZurickNashville$231K
- Mark ZenkerNashville$225K
- George CrossleyNashville$197K
- Joel PharesNashville$171K
- Arvindh KanagasundramNashville$161K
- Jessica HustonNashville$109K
- Joshua BeckmanNashville$106K
- Travis RichardsonNashville$87K
- Aniket RaliNashville$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.